FDA Approves NRx Preservative-Free Ketamine Ahead of Nov. 10 Target
Key Facts
The U.S. Food and Drug Administration has approved NRx Pharmaceuticals’ ANDA for preservative-free ketamine, clearing the way for a transition to commercial launch. The company announced the development in a statement issued on Oct. 29, ahead of the GDUFA target date of Nov. 10, 2026. That date was a review target, not a mandatory deadline, as the company explained in its previous disclosure. NRx said it would discuss the regulatory development and next steps for the launch on a call scheduled for Oct. 30. It added that it already has drug supplies ready for commercial release pending approval of the application, without specifying when shipments would begin or the expected financial impact.
The decision ends a review period that continued after the FDA deemed the application substantially complete in December 2025 and set July 29, 2026, as the target for completing the final review, with marketing approval possible. The timetable later changed after the agency reclassified an application amendment from a major amendment to a minor amendment, according to NRx’s announcement on Sept. 15. In the acknowledgment letter cited in the company’s disclosure, the GDUFA target date was revised to Nov. 10, 2026. Approval before that date does not mean it was a legally binding deadline, but that the decision came ahead of the review target. These dates show how the application moved from a July review target to the revised November date before approval was issued.
The company said in August that the initial review had identified no major deficiencies related to the drug or its components, the proposed labeling, manufacturing or product review. It said the remaining issue at the time concerned a manufacturer certification for a luer-lock packaging system, which it said was already used by three FDA-approved ANDA products. This followed a company statement describing the obstacle as related to packaging certification, not a problem with the ketamine formulation or its drug data. NRx then announced approval of the application in October, without attributing the decision to any specific reason in the available facts. This sequence places the final regulatory issue in the context of a review in which the company said no major drug-related deficiencies had been identified.
Approval was also preceded by steps to verify manufacturing readiness. On Oct. 19, NRx said it had completed the manufacture of three commercial batches of preservative-free ketamine, in line with FDA process validation requirements and good manufacturing practices. These batches provide a manufacturing basis for the product, while commercial release remained tied to ANDA approval, according to the company. It also said it had completed analysis of two years of real-time stability data at room temperature. The company said the data showed no degradation in purity, potency or sterility in the absence of preservatives, characteristics it linked to the product’s profile and stability.
The company says it has supplies ready for commercial release pending approval of the product, which it described as intended for a market facing a drug shortage. In an earlier statement, it said it aimed to supply U.S. hospitals and clinics as soon as approval was obtained, but the available information did not specify inventory volume or a delivery schedule. In December 2025, NRx estimated the global generic ketamine market at about $750 million annually and said it was prepared to scale manufacturing to 1 million vials a month. These were estimates and plans the company announced at the time, not sales figures or production capacity currently in use. Its discussion of commercial steps on the announced call will offer a way to learn how it intends to move from the readiness it described to supplying the product.
The product carries the trade name KETAFREE, and NRx said in a December 2025 statement that it was designed for use in all currently approved indications for ketamine. The company distinguished this application from NRX-100, a new drug application it is developing for depression accompanied by suicidal ideation. In its Oct. 29 statement, it also described itself as a clinical-stage biopharmaceutical company developing treatments based on an NMDA receptor platform to target central nervous system disorders. This background places the generic ketamine product within the company’s commercial and regulatory strategy, while keeping it distinct from the NRX-100 research program. The company was scheduled to hold its call at 8:30 a.m. Eastern time on Oct. 30 to discuss the approval and next steps for the launch.